Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →
Mebendazole †Rx
Repurposed Rx: Tubulin disruptor, VEGF ↓, apoptosis ↑; phase I/II active in glioma/ovarian/colorectal; chemo synergies.
Educational only, not medical advice. OncoForge makes no claim that Mebendazole †Rx treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Key Takeaway
Anthelmintic repurposed for oncology: Potent tubulin disruptor with anti-angiogenic and pro-apoptotic actions; strong preclinical efficacy and emerging phase I/II signals, particularly in brain and gynecologic cancers.
Extensive in vitro/in vivo validation; phase I/II trials confirm safety/PK and signals in glioma (NCT01729260), ovarian (NCT03925662); synergies with TMZ/cisplatin; ongoing 2025 trials in H&N/pancreatic.
Mebendazole (MBZ) inhibits microtubule polymerization by binding β-tubulin, disrupting mitosis and inducing G2/M arrest; suppresses VEGF/HIF-1α signaling for anti-angiogenic effects; activates intrinsic apoptosis via caspase-3/9, Bax upregulation, and p53 stabilization; additional targets include Hedgehog, NF-κB, and kinase pathways; penetrates BBB effectively; preclinical and early clinical data in glioma, ovarian, colorectal, and other solid tumors.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
Combinations reported in the literature, not a protocol or a recommendation.
Temozolomide: Improved PFS/OS in recurrent glioma phase II.
Cisplatin: Reverses resistance, boosts apoptosis in ovarian PDX.
Docetaxel: Synergistic microtubule disruption in prostate/ACC models.
Curcumin: Enhanced NF-κB/apoptosis inhibition in colorectal.
Overlapping mechanisms
Tubulin: Overlaps with taxanes/vinca; potential additive neuropathy.
Angiogenesis: May amplify with bevacizumab; monitor vascular events.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
This laboratory study tested European mistletoe (Viscum album) extract on a canine high-grade astrocytoma cell line (SDT-3G) and measured effects alone and combined with mebendazole. Mistletoe extract had an IC50 of 5.644 ± 0.09 SD µg/mL in these cells, and combining mistletoe (5 µg/mL) with mebendazole (0.03 µM) increased cell death compared with each drug alone. The authors conclude the results support further in vitro and in vivo study in dogs.
The IC50 for mistletoe alone was 5.644 ± 0.09 SD µg/mL against SDT-3G cells in vitro.
Mebendazole was applied at a previously determined IC50 of 0.03 µM in combination experiments.
The addition of mistletoe at 5 µg/mL to mebendazole at 0.03 µM led to increased cell death compared to what would be expected for each drug separately.
Limitations: In vitro study only (cell line); no in vivo or clinical data.; Single canine glioma cell line (SDT-3G) used — limited generalizability across tumors.; Abstract does not report sample size, replicate numbers, or statistical test results for the combination effect.; No detailed mechanistic investigation reported in the abstract.; No safety, pharmacokinetics, or efficacy data in animals or humans..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Mebendazole †Rx's evidence base, and anything that's been retracted.
Cancers where Mebendazole †Rx reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Preclinical only: lab / animal (2)
Canine high-grade astrocytoma1 positive1 lab
Limitations: In vitro study only (cell line); no in vivo or clinical data.; Single canine glioma cell line (SDT-3G) used — limited generalizability across tumors.; Abstract does not report sample size, replicate numbers, or statistical test results for the combination effect.; No detailed mechanistic investigation reported in the abstract.; No safety, pharmacokinetics, or efficacy data in animals or humans..
Limitations: In vitro study only (cell line); no in vivo or clinical data.; Single canine glioma cell line (SDT-3G) used — limited generalizability across tumors.; Abstract does not report sample size, replicate numbers, or statistical test results for the combination effect.; No detailed mechanistic investigation reported in the abstract.; No safety, pharmacokinetics, or efficacy data in animals or humans..
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
These are doses as studied or reported, never a recommendation. The right amount of Mebendazole †Rx depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Ranges seen in adjunct / practice use: 100–1500 mg/day (po) divided BID-TID; with fatty meal for absorption, Anti-parasitic 100 mg BID; oncology trials 200-500 mg BID (up to 1500 mg/day in glioma); fatty food increases bioavailability 2-3x..
No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →
Appears in these protocol claims
Mebendazole †Rx is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.